



A/Habert # 7

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Information Disclosure
Statement

DOCKET NO.: D6126
SERIAL NO.: 09/721,864
APPLICANT: Scheinberg et al.
FILING DATE: November 24, 2000
GROUP:

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
---------------------	--------------------	------	------	-------	----------	----------------

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Publication: Patent Cooperation Treaty (PCT)
Translation: English
Document Number: WO 91/09058 Date: 6/27/91
Country: Great Britain
Class Or Subclass C07K 15/00
Patent: Yes ☐ No ☒
Title: Therapeutic Uses of The Hypervariable Region of Monoclonal Antibody M195 and Constructs Thereof

Publication: Patent Cooperation Treaty (PCT)
Translation: English
Document Number: 0 585 986 A1 Date: 7/22/93
Country: Germany
Class Or Subclass A61K 43/00
Patent: Yes ☐ No ☒
Title: Method and Means For Site Directed Therapy

Publication: Patent Cooperation Treaty (PCT)
Translation: English
Document Number: 0 282 057 A2 Date: 3/10/88
Country: Germany
Class Or Subclass A61K 43/00
Patent: Yes ☐ No ☒
Title: Chemo-radio-immuno-conjugates.

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

a. McDevitt M. R. et al. *Bismuth Labeled Antibodies for Therapy of Prostate Carcinomas: Preclinical Studies*. Journal of Nuclear Medicine, Society of Nuclear Medicine, vol. 39, no. 5, 1998, pp. 223-224.

b. Larsen R.H. et al. *Intratumour injection of immunoglobulins labelled with the α -particle emitter 211 At: analyses of tumour retention, microdistribution and growth delay*. British Journal of Cancer. Vol. 77, no. 7, 1998, pp. 1115-1122.

c. Sgouros G. et al. *Pharmacokinetics and dosimetry of and alpha-particle emitter labeled anti-CD33 antibody ((213Bi)HuM195) in patients with leukemia*. Journal of Nuclear Medicine. Vol. 38, no. 5, 1997, pp. 231.

708
d. Jurcic J. G. et al. *Targeted alpha-particle therapy for myeloid leukemias: A phase I trial of bismuth-213-HuM195 (anti-CD33)*. Memorial Sloan-Kettering Cancer Center. Vol. 90, no.10, 1997, pp. 504A.

JUL 26 2002
e. Kennel S. et al. *Vascular Targeted Radioimmunotherapy with 213Bi-An α -Particle Emitter*. *Nuclear Medicine & Biology*. Vol. 25, no. 3, 1998, pp. 241-246.

f. Liu, H. et al. *Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen Also React with Tumor Vascular Endothelium1*. *Cancer Research*. Vol. 57, 1997, no. 17 pp. 3629-3634.

Examiner

M. T. DAVIS

Date Considered

11/12/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

RECEIVED

JUL 29 2002

TECH CENTER 1600/2800